Quantum Biopharma (QNTM) Other Gross PP&E Adjustments (2019 - 2026)
Quantum Biopharma recorded quarterly Other Gross PP&E Adjustments of -$83048.0 in Q1 2026, up 18.84% quarter-over-quarter from -$102320.0 in Q4 2025, and down 137.81% year-over-year from $219645.7 in Q1 2025.
Quantum Biopharma's Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at -$83048.0 for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments fell 137.81% year-over-year to -$83048.0; the TTM figure through Mar 2026 stood at -$83048.0 (down 137.81% YoY), while the FY2025 annual figure was -$102320.0, down 91.3% from the prior year.
- Other Gross PP&E Adjustments came in at -$83048.0 for Q1 2026 at Quantum Biopharma, up from -$102320.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$8244.0 in Q2 2024 to a low of -$192422.0 in Q3 2022.
- A 5-year average of -$99679.5 and a median of -$102320.0 in 2025 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments surged 89.94% in 2024 and tumbled 1793.93% in 2025, its largest moves.
- Quantum Biopharma's Other Gross PP&E Adjustments stood at -$155196.0 in 2022, then surged by 70.83% to -$45270.0 in 2023, then declined by 18.15% to -$53488.0 in 2024, then plunged by 91.3% to -$102320.0 in 2025, then rose by 18.84% to -$83048.0 in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$83048.0, -$102320.0, and -$121270.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -75.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83,048.00 |
| Mar 31, 2026 | -83,048.00 |
| Dec 31, 2025 | -102,320.00 |
| Dec 31, 2025 | -102,320.00 |
| Sep 30, 2025 | -121,270.00 |
| Sep 30, 2025 | -121,270.00 |
| Jun 30, 2025 | -156,136.00 |
| Jun 30, 2025 | -156,136.00 |
| Mar 31, 2025 | -34,922.00 |
| Mar 31, 2025 | -34,922.00 |
| Dec 31, 2024 | -53,488.00 |
| Dec 31, 2024 | -53,488.00 |
| Sep 30, 2024 | -72,374.00 |
| Sep 30, 2024 | -72,374.00 |
| Jun 30, 2024 | -8,244.00 |
| Jun 30, 2024 | -8,244.00 |
| Sep 30, 2023 | -45,270.00 |
| Sep 30, 2023 | -45,270.00 |
| Jun 30, 2023 | -81,957.00 |
| Jun 30, 2023 | -81,957.00 |
| Mar 31, 2023 | -118,779.00 |
| Mar 31, 2023 | -118,779.00 |
| Dec 31, 2022 | -155,196.00 |
| Dec 31, 2022 | -155,196.00 |
| Sep 30, 2022 | -192,422.00 |
| Sep 30, 2022 | -192,422.00 |
| Jun 30, 2022 | -122,621.00 |
| Jun 30, 2022 | -122,621.00 |
| Mar 31, 2022 | -147,146.00 |
| Mar 31, 2022 | -147,146.00 |
| Dec 31, 2021 | -168,307.00 |
| Dec 31, 2021 | -168,307.00 |
| Dec 31, 2019 | -96,512.87 |
| Dec 31, 2019 | -96,512.87 |